RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Peking University People's Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Peking University People's Hospital北京大学人民医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07018063, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 16 years to 45 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).

    Inclusion criterion 4

  3. For gastric body cancer: clinical stage cT3-T4a N+ M0;

    Inclusion criterion 5

    For GEJ cancer: clinical stage cT2-T4a N+ M0;

    Inclusion criterion 6

  4. Karnofsky performance score ≥70% or ECOG performance status 0-1;

    Inclusion criterion 3

  5. Hemoglobin ≥90 g/L

    Inclusion criterion 13

    Absolute neutrophil count (ANC) ≥1.5×10⁹/L

    Inclusion criterion 14

    Platelets ≥100×10⁹/L

    Inclusion criterion 15

    ALT and AST ≤2.5× upper limit of normal (ULN)

    Inclusion criterion 16

    Alkaline phosphatase (ALP) ≤2.5× ULN

    Inclusion criterion 17

    Total bilirubin <1.5× ULN

    Inclusion criterion 18

    Serum creatinine <1× ULN

    Inclusion criterion 19

  6. Patients with HER-2 positive gastric cancer, as determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH);

    Exclusion criterion 2

    History of other malignancies within the past 5 years;

    Exclusion criterion 6

  7. Pregnant or breastfeeding women;

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07018063, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Participants must meet all of the following inclusion criteria:
  • Male or female, aged ≥16 and ≤45 years;
  • Karnofsky performance score ≥70% or ECOG performance status 0-1;
  • Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).
  • For gastric body cancer: clinical stage cT3-T4a N+ M0;
  • For GEJ cancer: clinical stage cT2-T4a N+ M0;
  • For cT4b Nany M0 cases: location may be gastric body or GEJ.
  • Staging is based on contrast-enhanced CT, MRI (if needed), and endoscopic ultrasonography (EUS) (if needed);
  • Assessed as resectable after multidisciplinary team (MDT) discussion;
  • Surgical evaluation confirms that D2 radical gastrectomy is feasible;
  • Sufficient physical condition and organ function to tolerate major abdominal surgery;
  • Baseline laboratory tests meet the following criteria:
  • Hemoglobin ≥90 g/L
  • Absolute neutrophil count (ANC) ≥1.5×10⁹/L
  • Platelets ≥100×10⁹/L
  • ALT and AST ≤2.5× upper limit of normal (ULN)
  • Alkaline phosphatase (ALP) ≤2.5× ULN
  • Total bilirubin <1.5× ULN
  • Serum creatinine <1× ULN
  • Serum albumin ≥30 g/L
  • No severe comorbidities that may limit life expectancy to <3 years;
  • Participant is willing and able to comply with the study protocol during the study period;
  • Written informed consent must be signed before screening. Participants must understand their right to withdraw at any time without any loss of benefits;
  • Willing to provide blood and tissue samples.

Exclusion Criteria:

  • Participants meeting any of the following criteria will be excluded:
  • Patients with HER-2 positive gastric cancer, as determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH);
  • Patients with dMMR (deficient mismatch repair) or MSI-H (microsatellite instability-high) tumors, as determined by IHC;
  • Pregnant or breastfeeding women;
  • Prior treatment for gastric cancer with cytotoxic chemotherapy, radiotherapy, or immunotherapy;
  • History of other malignancies within the past 5 years;
  • Active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis;
  • Active inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis;
  • Currently receiving systemic corticosteroids or other immunosuppressive therapy;
  • Prior organ transplantation or use of anti-rejection medications;
  • Active tuberculosis, HIV infection, or severe active hepatitis B or C;
  • History of uncontrolled epilepsy, central nervous system disorders, or psychiatric illnesses that, in the investigator's judgment, may interfere with informed consent or compliance with oral medication;
  • Clinically significant (active) cardiac diseases, including symptomatic coronary artery disease, NYHA class II or above congestive heart failure , severe arrhythmias requiring medical intervention, or myocardial infarction within the past 12 months;
  • Presence of upper gastrointestinal obstruction that may impair the oral intake or absorption of S-1;
  • Severe uncontrolled recurrent infections or other uncontrolled serious comorbidities;
  • Use of any investigational drugs within 4 weeks prior to study enrollment.

Quoted from ClinicalTrials.gov, NCT07018063, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07018063, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07018063